New York, Jan 13, 2026, 16:15 EST — After-hours
- Kiniksa shares dropped roughly 6% on Tuesday following the release of an updated ARCALYST outlook
- The drugmaker projected ARCALYST net product revenue for 2026 to be between $900 million and $920 million
- Wedbush raised its price target to $50, pointing to increased prescriber numbers and extended therapy use
Kiniksa Pharmaceuticals International, plc saw its shares drop 6.1% to $38.61 on Tuesday, following the release of updated revenue forecasts for its key drug ARCALYST. The stock briefly dipped to an intraday low of $38.27.
The move matters because ARCALYST is carrying the load: it serves as the company’s primary commercial driver and bankrolls the longer-acting follow-on program. Kiniksa’s 2026 outlook arrives early, just as biotech investors are eager to revise growth expectations.
Kiniksa’s update arrived as executives made the rounds at the J.P. Morgan Healthcare Conference in San Francisco, a crucial event where firms vie to capture investor interest for the year. Running Jan. 12-15, the conference buzz often sets the tone for price moves in the weeks that follow.
On Monday, Kiniksa reported that ARCALYST (rilonacept) pulled in unaudited net product revenue of $677.5 million for 2025 and projected $900 million to $920 million for 2026. CEO Sanj K. Patel noted that ARCALYST is “increasingly becoming the preferred second line treatment” for recurrent pericarditis, the recurring inflammation of the heart’s lining. The company also revealed an 8.4% gross-to-net rate for 2025, reflecting discounts and rebates, and closed the year with $414.1 million in cash and zero debt. Nasdaq press release
A deck from the J.P. Morgan conference labeled ARCALYST as the first—and only—FDA-approved treatment for recurrent pericarditis, pitching it as a “steroid-sparing” alternative to avoid the side effects of prolonged steroid use. It also emphasized the company’s efforts to expand beyond just the most severe cases, aiming to fuel the next growth phase. MarketScreener deck
Wedbush’s David Nierengarten bumped Kiniksa’s price target to $50 from $48, maintaining an Outperform rating, The Fly reports. The analyst highlighted that growth is fueled by both a wider pool of prescribers and patients staying on therapy longer.
That said, Kiniksa’s own projections suggest a chillier scenario. The midpoint of its 2026 forecast points to roughly mid-30% growth from 2025, significantly under the roughly 62% surge the company expects for 2025.
Biotech benchmarks barely budged, indicating Tuesday’s sell-off hit individual stocks more than the sector as a whole.
ARCALYST’s growth will depend heavily on how aggressively Kiniksa can expand its reach into the larger patient base, and how payers react as volume increases. If uptake falters or pricing pressure widens the gross-to-net spread, the impact would be swift for a company still reliant on a single key product.
Investors will also watch the pipeline timeline closely. Kiniksa has set its sights on releasing Phase 2 dose-focusing data for KPL-387 in the second half of 2026, creating a lengthy stretch where commercial results will be the main updates.
Traders are set to dive into the replay and related materials from Kiniksa’s J.P. Morgan presentation, which the company said should be available in roughly 48 hours. According to Nasdaq data, Kiniksa is expected to report earnings near Feb. 24, 2026.
